Review
Sep 2026
Drug-Induced Liver Injury (DILI) in clinical trials: Views and practical updates from DILI specialists at FDA.
Eight key topics that may benefit from review, clarification, research, and discussion between industry, academia, and regulators as the FDA works to address DILI risk assessment are highlighted.
P. Hayashi, Mark I. Avigan
· Hepatology · 0 citations